Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06777472 | NOT YET RECRUITING | Asthma

Clinical Study of Lung-benefiting Moxibustion Reduce Exacerbations of Asthma
Sponsor:

C UI order F

Information provided by (Responsible Party):

C UI order F

Brief Summary:

For patients with poor asthma control, on the basis of treatment guided by GINA guidelines, lung-benefiting moxibustion treatment will be given, and it will be applied 10 days before "early onset", once every 10 days, and the follow-up was 45 weeks, 1 cycle per year, for 2 consecutive cycles (2 years). The annual number of flare-up of asthma patients will be used as the main outcome index to evaluate the clinical effect of lung-benefiting moxibustion on reducing exacerbations of asthma. By observing immunoglobulin, T cell subsets and other indicators, the advantage population and mechanism of moxibustion in treating patients with poor asthma control will be clarified.

Condition or disease

Asthma

Intervention/treatment

lung-benefiting moxibustion

The specific drug comes from "GINA (2024)"

Phase

NA

Study Type : INTERVENTIONAL
Estimated Enrollment : 384 participants
Masking : SINGLE
Primary Purpose : OTHER
Official Title : Clinical Study on Reducing Exacerbations of Asthma by Lung-benefiting Moxibustion Based on "Winter Disease Cured in Summer"
Actual Study Start Date : 2025-07
Estimated Primary Completion Date : 2026-09
Estimated Study Completion Date : 2027-08

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years to 80 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Patients who meet the diagnosis of asthma (remission);
  • * Patients with poor clinical control;
  • * Age 18-80 years old;
  • * Voluntarily undergo treatment and sign an informed consent form;
Exclusion Criteria
  • * Patients combined with pulmonary abscess, pulmonary fibrosis, active pulmonary tuberculosis, bronchiectasis or other lung diseases;
  • * Patients with severe cardiovascular and cerebrovascular diseases (malignant arrhythmia, unstable angina pectoris, acute myocardial infarction, cardiac functional classification≥III, stroke, cerebral hemorrhage, etc.)；
  • * Patients with severe liver diseases (liver cirrhosis, portal hypertension, bleeding due to esophageal and gastric varices, etc.) or severe kidney diseases (renal dialysis, kidney transplantation, etc.)；
  • * Patients with confusion, various mental disorders, etc., who are unable to communicate normally;
  • * Pregnant and lactating women;
  • * Patients with heat phlegm pattern through TCM pattern differentiation；
  • * Patients participating in other clinical trials within 1 month prior to enrollment;
  • * Received TCM external treatment such as lung-benefiting moxibustion for 1 year;
  • * Patients allergic to moxibustion drugs, smoke, etc.
Clinical Study of Lung-benefiting Moxibustion Reduce Exacerbations of Asthma

Location Details

NCT06777472

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

No Location Found